title: Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects.
abstract: We studied the effects of dietary supplementation with an encapsulated fish oil concentrate (Maxepa) on platelet function, fibrinolysis, and plasma lipids and lipoproteins in 9 normal subjects, 10 patients with type IV hyperlipoproteinemia, and 6 with type IIB hyperlipoproteinemia. After a baseline period, the subjects crossed over randomly between treatment periods with Maxepa (providing 3.24 g eicosapentaenoic acid and 2.16 g docosahexaenoic acid per day) and safflower oil (used as a control), given for 6 weeks each. Administration of Maxepa led to a slight prolongation of the bleeding time in all groups and to modest inhibition of platelet aggregation in the type IV hyperlipoproteinemics and normal subjects, with partial (41%) inhibition of thromboxane synthesis from baseline levels noted in the normal group. Plasma total fibrinolytic actively did not change significantly in any group. Maxepa treatment resulted in a marked decrease in triglyceride and VLDL-cholesterol and a slight increase in HDL-cholesterol was noted after Maxepa in the type IV hyperlipoproteinemics (4.11 +/- 0.13 mmol/l vs. 3.10 +/- 0.16 mmol/l, Maxepa vs. safflower oil). We conclude that dietary supplementation with fish oil results in a relatively minor degree of inhibition of platelet function in normal and hyperlipoproteinemic subjects, and a potentially adverse increase in LDL-cholesterol in type IV hyperlipoproteinemics.
authors.affiliation: Department of Pathology, University of Kansas School of Medicine, Kansas City.
authors.forename: M L
authors.initials: ML
authors.lastname: Zucker
authors.forename: D S
authors.initials: DS
authors.lastname: Bilyeu
authors.forename: G M
authors.initials: GM
authors.lastname: Helmkamp
authors.forename: W S
authors.initials: WS
authors.lastname: Harris
authors.forename: C A
authors.initials: CA
authors.lastname: Dujovne
mesh_terms: D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000502:physiology*; D004042:Dietary Fats, Unsaturated / Q000627:therapeutic use*; D004281:Docosahexaenoic Acids; D004311:Double-Blind Method; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000178:diet therapy*; D006953:Hyperlipoproteinemia Type IV / Q000178:diet therapy*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013997:Time Factors
chemical_list: D004042:Dietary Fats, Unsaturated; D004338:Drug Combinations; D005231:Fatty Acids, Unsaturated; D008055:Lipids; C045153:Maxepa; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid